$SLDB Доктор Карл будет докладать 19 Мая перед открытием рынка в 16:15 по Москве. American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting – May 16-19, 2022, Washington, D.C. Carl Morris, Ph.D., Chief Scientific Officer at Solid Biosciences, will present data from the ongoing Phase I/II IGNITE DMD clinical trial of SGT-001 microdystrophin gene therapy in patients with Duchenne. Dr. Morris will also present pre-clinical data from a non-human primate study of a novel capsid utilized in SGT-003, the company’s next-generation microdystrophin gene therapy for Duchenne. Details of the presentation are as follows: Oral presentation: IGNITE DMD Study of SGT-001 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy: Long-Term Outcomes and Biomarker Update Abstract number: 1193 Session: Clinical Trials Spotlight Symposium Date and time: Thursday, May 19, 9:15-9:30 a.m. ET